Invesco Ltd. Cure Vac N.V. Transaction History

Invesco Ltd.

$499 Billion
Q3 2024

A detailed history of Invesco Ltd. transactions in Cure Vac N.V. stock. As of the latest transaction made, Invesco Ltd. holds 11,526 shares of CVAC stock, worth $31,696. This represents 0.0% of its overall portfolio holdings.

Number of Shares

11,526

Previous 12,923 10.81%

Holding current value

$31,696

Previous $43,000 23.26%

% of portfolio

0.0%

Previous 0.0%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 12, 2024	SELL	$2.74 - $3.79 $3,827 - $5,294	-1,397 Reduced 10.81%	11,526 $33,000
Q2 2024 Aug 13, 2024	BUY	$2.31 - $4.99 $3,760 - $8,123	1,628 Added 14.41%	12,923 $43,000
Q1 2024 May 14, 2024	BUY	$2.94 - $4.34 $33,207 - $49,020	11,295 New	11,295 $34,000
Q4 2022 Feb 13, 2023	SELL	$5.75 - $8.5 $1,828 - $2,703	-318 Reduced 1.32%	23,776 $143,000
Q3 2022 Nov 14, 2022	SELL	$7.48 - $15.24 $8,878 - $18,089	-1,187 Reduced 4.7%	24,094 $189,000
Q2 2022 Aug 15, 2022	SELL	$13.18 - $19.41 $847,394 - $1.25 Million	-64,294 Reduced 71.78%	25,281 $344,000
Q1 2022 May 16, 2022	BUY	$14.73 - $35.25 $722,506 - $1.73 Million	49,050 Added 121.04%	89,575 $1.76 Million
Q4 2021 Feb 14, 2022	BUY	$33.72 - $48.22 $419,274 - $599,567	12,434 Added 44.26%	40,525 $1.39 Million
Q3 2021 Nov 15, 2021	BUY	$49.26 - $74.5 $131,819 - $199,362	2,676 Added 10.53%	28,091 $1.53 Million
Q2 2021 Aug 17, 2021	BUY	$56.91 - $127.53 $1.45 Million - $3.24 Million	25,415 New	25,415 $1.87 Million

Others Institutions Holding CVAC

# of Institutions

Shares Held

12.3M

Call Options Held

164K

Put Options Held

117K

View Full List

About CureVac N.V.

Ticker CVAC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,467,008
Market Cap $516M
Description
CureVac N.V., a clinical-stage biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202, a prophylactic mRNA-based vaccine, which ...

More about CVAC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.

Account